CLSD - クリアサイド・バイオメディカル (Clearside Biomedical Inc.)

CLSDのニュース

   Clearside Biomedical, Inc.''s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript  2022/05/12 01:11:06 Seeking Alpha
Clearside Biomedical, Inc. (NASDAQ:NASDAQ:CLSD) Q1 2022 Earnings Conference Call May 11, 2022, 04:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President…
   Clearside Biomedical GAAP EPS of -$0.13 misses by $0.10, revenue of $0.35M misses by $5.85M  2022/05/11 20:12:03 Seeking Alpha
Clearside Biomedical press release (NASDAQ:CLSD): Q1 GAAP EPS of -$0.13 misses by $0.10.Revenue of $0.35M (+1066.7% Y/Y) misses by $5.85M.
   Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update  2022/05/11 20:05:00 GlobeNewswire
- First Approved Suprachoroidal Product, XIPERE ® , Now Commercially Available in U.S. -
   Clearside Biomedical Q1 2022 Earnings Preview (NASDAQ:CLSD)  2022/05/10 21:35:05 Seeking Alpha
Clearside Biomedical (CLSD) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close.The consensus EPS Estimate is -$0.01 and the consensus Revenue…
   Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022  2022/04/29 11:05:00 GlobeNewswire
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
   Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next?  2022/04/09 18:00:00 Marketing Sentinel
In last trading session, Clearside Biomedical Inc. (NASDAQ:CLSD) saw 0.36 million shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $2.17 trading at -$0.2 or -8.44% at ring of the bell on the day assigns it a market valuation of $127.70M. That closing price of CLSD’s stock is … Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next? Read More »
   Clearside Biomedical to Present at the Needham Virtual Healthcare Conference  2022/04/06 11:05:00 GlobeNewswire
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at the Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.
   Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners?  2022/03/28 13:31:00 Benzinga
NEW YORK , March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP. … Full story available on Benzinga.com
   Bausch Health, Clearside launch vision disorder therapy Xipere in US  2022/03/28 12:15:52 Seeking Alpha
Bausch Health (BHC) and Clearside Biomedical (CLSD) launched eye disorder therapy Xipere (triamcinolone acetonide injectable suspension) in the U.S.The companies said Xipere is the…
   Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now.  2022/03/22 15:30:00 Stocks Register
Clearside Biomedical Inc. (NASDAQ:CLSD) price closed lower on Monday, March 21, dropping -10.31% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $2.62, with intraday deals fluctuated between $2.33 and $2.7124. … Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now. Read More »
   FY2021 Earnings Forecast for Clearside Biomedical, Inc. Issued By Wedbush (NASDAQ:CLSD)  2021/12/24 11:26:42 Dakota Financial News
Clearside Biomedical, Inc. (NASDAQ:CLSD) – Stock analysts at Wedbush reduced their FY2021 EPS estimates for Clearside Biomedical in a research note issued to investors on Tuesday, December 21st. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.42). Wedbush […]
   HC Wainwright Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD)  2021/12/23 08:46:41 Dakota Financial News
HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report report published on Wednesday, Price Targets.com reports. The firm currently has a $10.00 price target on the stock. CLSD has been the subject of several other reports. JMP Securities restated a buy rating and set a $11.00 target price []
   Diabetic Macular Edema Market Size, Landscape, Industry Analysis, Business Outlook, Current and Future Growth By 2028 | Pfizer Inc, Allergan PLC, Novartis AG, Clearside Biomedical Inc, Ariam Pharmaceuticals, Valeant Pharmaceuticals, Regenron PLC, Bayer AG  2021/12/14 11:13:00 OpenPR
New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to
   Clearside Biomedical to join Nasdaq Biotechnology Index  2021/12/13 23:00:01 Seeking Alpha
   Clearside Biomedical Added to the Nasdaq Biotechnology Index  2021/12/13 21:05:00 Intrado Digital Media
ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

calendar